Allspring Global Investments Holdings LLC Has $3.59 Million Position in Twist Bioscience Co. (NASDAQ:TWST)

Allspring Global Investments Holdings LLC reduced its stake in Twist Bioscience Co. (NASDAQ:TWST) by 5.6% during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 79,519 shares of the company’s stock after selling 4,686 shares during the period. Allspring Global Investments Holdings LLC owned about 0.14% of Twist Bioscience worth $3,593,000 as of its most recent filing with the Securities and Exchange Commission.

Other hedge funds also recently made changes to their positions in the company. EdgeRock Capital LLC acquired a new stake in shares of Twist Bioscience in the 2nd quarter valued at approximately $43,000. Blue Trust Inc. raised its holdings in Twist Bioscience by 2,912.8% in the 2nd quarter. Blue Trust Inc. now owns 1,175 shares of the company’s stock valued at $58,000 after buying an additional 1,136 shares during the last quarter. DekaBank Deutsche Girozentrale bought a new position in Twist Bioscience in the 2nd quarter valued at approximately $61,000. Nisa Investment Advisors LLC raised its holdings in Twist Bioscience by 31.3% in the 2nd quarter. Nisa Investment Advisors LLC now owns 2,288 shares of the company’s stock valued at $113,000 after buying an additional 546 shares during the last quarter. Finally, CWM LLC raised its holdings in Twist Bioscience by 27.4% in the 2nd quarter. CWM LLC now owns 2,437 shares of the company’s stock valued at $120,000 after buying an additional 524 shares during the last quarter.

Insider Activity

In other news, CEO Emily M. Leproust sold 13,605 shares of Twist Bioscience stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total value of $587,872.05. Following the completion of the sale, the chief executive officer now owns 481,918 shares in the company, valued at $20,823,676.78. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. In related news, insider Dennis Cho sold 709 shares of Twist Bioscience stock in a transaction on Monday, August 5th. The shares were sold at an average price of $39.93, for a total value of $28,310.37. Following the completion of the sale, the insider now owns 78,996 shares of the company’s stock, valued at approximately $3,154,310.28. This trade represents a 0.00 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, CEO Emily M. Leproust sold 13,605 shares of Twist Bioscience stock in a transaction on Wednesday, October 2nd. The shares were sold at an average price of $43.21, for a total transaction of $587,872.05. Following the completion of the sale, the chief executive officer now directly owns 481,918 shares of the company’s stock, valued at approximately $20,823,676.78. The trade was a 0.00 % decrease in their position. The disclosure for this sale can be found here. Insiders sold 42,300 shares of company stock worth $1,801,822 in the last quarter. 3.92% of the stock is owned by corporate insiders.

Twist Bioscience Stock Up 4.7 %

NASDAQ:TWST opened at $42.52 on Tuesday. The company has a fifty day moving average of $43.80 and a 200-day moving average of $44.87. The firm has a market capitalization of $2.49 billion, a P/E ratio of -11.13 and a beta of 1.77. Twist Bioscience Co. has a twelve month low of $14.42 and a twelve month high of $60.90.

Twist Bioscience (NASDAQ:TWST) last released its quarterly earnings data on Friday, August 2nd. The company reported ($1.47) earnings per share for the quarter, missing the consensus estimate of ($0.76) by ($0.71). The company had revenue of $81.50 million during the quarter, compared to the consensus estimate of $77.40 million. Twist Bioscience had a negative net margin of 74.63% and a negative return on equity of 32.17%. The business’s revenue was up 27.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned ($1.01) EPS. On average, analysts anticipate that Twist Bioscience Co. will post -3.13 EPS for the current fiscal year.

Analyst Ratings Changes

A number of research analysts recently issued reports on TWST shares. Leerink Partners raised their price objective on shares of Twist Bioscience from $45.00 to $48.00 and gave the company a “market perform” rating in a report on Thursday, October 17th. Robert W. Baird raised their price objective on shares of Twist Bioscience from $40.00 to $46.00 and gave the company an “outperform” rating in a report on Monday, August 5th. JPMorgan Chase & Co. raised their price target on shares of Twist Bioscience from $28.00 to $35.00 and gave the stock an “underweight” rating in a report on Monday, August 5th. Evercore ISI raised their price target on shares of Twist Bioscience from $52.00 to $56.00 and gave the stock an “outperform” rating in a report on Tuesday, October 1st. Finally, The Goldman Sachs Group raised their price target on shares of Twist Bioscience from $45.00 to $55.00 and gave the stock a “buy” rating in a report on Tuesday, July 9th. One research analyst has rated the stock with a sell rating, one has issued a hold rating and seven have assigned a buy rating to the company’s stock. According to MarketBeat, Twist Bioscience presently has an average rating of “Moderate Buy” and a consensus price target of $51.22.

Twist Bioscience Company Profile

Twist Bioscience Corporation engages in the manufacture and sale of synthetic DNA-based products. The company offers synthetic genes and gene fragments used in product development for therapeutics, diagnostics, chemicals/materials, food/agriculture, data storage, and various applications within academic research by biotech, pharma, industrial chemical, and agricultural companies, as well as academic labs; Oligo pools used in targeted NGS, CRISPR gene editing, mutagenesis experiments, DNA origami, DNA computing, data storage in DNA, and other applications; and immunoglobulin G proteins for customers focused on the pursuit of drug discovery and development.